Table 3.
Independent Prognostic Factors for PFS
| Characteristics | PFS | ||||||
|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | ||||||
| HR | 95% CI | P | HR | 95% | P | ||
| Age (years) | ≤60 | Reference | 0.843 | Reference | |||
| >60 | 1.055 | 0.618–1.803 | |||||
| Gender | Male | Reference | 0.486 | Reference | |||
| Female | 0.909 | 0.694–1.190 | |||||
| WBC (*109) | ≤10 | Reference | 0.033 | Reference | 0.305 | ||
| >10 | 3.153 | 1.098–9.055 | 1.959 | 0.542–7.081 | |||
| HGB (g/L) | ≤120 | Reference | 0.031 | Reference | |||
| >120 | 0.533 | 0.301–0.945 | |||||
| PLT (*109) | ≤300 | Reference | 0.038 | Reference | 0.784 | ||
| >300 | 2.309 | 1.048–5.087 | 1.155 | 0.413–3.227 | |||
| ALT (U/L) | ≤50 | Reference | 0.106 | Reference | |||
| >50 | 1.644 | 0.900–3.003 | |||||
| AST (U/L) | ≤40 | Reference | 0.174 | Reference | |||
| >40 | 1.568 | 0.820–3.001 | |||||
| ALP (U/L) | ≤125 | Reference | 0.181 | Reference | |||
| >125 | 1.478 | 0.833–2.622 | |||||
| GGT (U/L) | ≤60 | Reference | 0.376 | Reference | |||
| >60 | 1.275 | 0.745–2.182 | |||||
| ALB (g/L) | >40 | Reference | 0.217 | Reference | |||
| ≤40 | 0.703 | 0.402–1.230 | |||||
| TBIL (umol/L) | ≤20.5 | Reference | 0.294 | Reference | |||
| >20.5 | 1.373 | 0.760–2.481 | |||||
| IBIL(umol/L) | ≤15 | Reference | 0.212 | Reference | |||
| >15 | 1.617 | 0.761–3.435 | |||||
| CRP (ng/L) | ≤3 | Reference | 0.018 | Reference | 0.110 | ||
| >3 | 1.928 | 1.121–3.318 | 1.611 | 0.898–2.889 | |||
| HBSAg | Absence | Reference | 0.322 | Reference | |||
| Presence | 0.555 | 0.172–1.283 | |||||
| CEA (ng/mL) | ≤5 | Reference | 0.668 | Reference | |||
| >5 | 1.130 | 0.646–1.978 | |||||
| CA19-9 (U/mL) | ≤35 | Reference | 0.126 | Reference | |||
| >35 | 1.582 | 0.878–2.849 | |||||
| CA125 | ≤35 | Reference | 0.012 | Reference | 0.163 | ||
| >35 | 2.119 | 1.181–3.802 | 1.552 | 0.836–2.881 | |||
| Tumor size | ≤2 | Reference | Reference | ||||
| 2~4 | 2.917 | 0.680–12.512 | 0.150 | 2.562 | 0.577–11.372 | 0.216 | |
| >4 | 10.445 | 1.438–75.883 | 0.020 | 3.322 | 0.221–50.029 | 0.386 | |
| Tumor site | Head | Reference | 0.161 | Reference | |||
| Body/tail | 0.678 | 0.393–1.167 | |||||
| Tumor grade | Well | Reference | 0.006 | Reference | 0.019 | ||
| Moderate/Poor | 2.146 | 1.249–3.687 | 2.031 | 1.125–3.669 | |||
| Treatment | IRE | Reference | 0.013 | Reference | 0.045 | ||
| IRE+toripalimab | 0.274 | 0.099–0.759 | 0.342 | 0.119–0.978 | |||
| Chemotherapy before IRE | Absence | Reference | 0.988 | Reference | |||
| Presence | 0.996 | 0.565–1.754 | |||||
| Chemotherapy before IRE | S-1 | Reference | Reference | ||||
| AG | 0.989 | 0.502–1.949 | 0.975 | ||||
| FOLFIRINOX | 1.001 | 0.530–1.890 | 0.998 | ||||
Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; NI, not include, other abbreviations as in Table 1.